Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer.

Trial Profile

Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Glutathione/cisplatin (Primary) ; Glutathione/cisplatin (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Aug 2012 Actual patient number changed from 41 to 23.
    • 20 Aug 2012 Actual end date (1 Apr 2011) added as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top